OSU-19050, NCT04115163: Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer |
|
|
| Recruiting | 2 | 53 | US | Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Protein-bound Paclitaxel | Anne Noonan, National Cancer Institute (NCI) | Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC V8 | 12/24 | 12/24 | | |
NCT05363631: Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab |
|
|
| Recruiting | 1/2 | 55 | US | Selenomethionine (SLM), Axitinib, Pembrolizumab | Bilal G. Rahim, University of Iowa | Clear Cell Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic | 12/26 | 12/26 | | |
NCT05159050: Intraperitoneal Paclitaxel-loaded TPM for Treatment of Peritoneal Carcinomatosis |
|
|
| Recruiting | 1 | 30 | US | Paclitaxel-loaded tumor penetrating microparticles | Carlos Chan, Institute of Quantitative Systems Pharmacology (IQSP) | Peritoneal Carcinomatosis | 11/24 | 11/24 | | |
